Skip to main content

Fibrosis

Section edited by Mary Salvatore

The Fibrosis section aims to gather current high-quality research to better understand the process of normal tissue repair as well as the pathogenetic mechanisms responsible for the onset and progression of tissue fibrosis that leads to organ dysfunction and failure. Fibrosis is the common denominator in a variety of chronic diseases including idiopathic pulmonary fibrosis, liver cirrhosis, and ulcerative colitis, among others. These fibrotic diseases affect a vast number of people across the world significantly impacting the quality of their life and increasing health care costs.

The section will focus on high-quality research from basic science to clinical trials. The expert members of our Editorial Board are committed to ensuring a productive scientific discussion and welcome your thought-provoking contributions to Fibrosis.


Page 2 of 2

  1. Cancer remains the leading cause of death around the world. In cancer treatment, over 50% of cancer patients receive radiotherapy alone or in multimodal combinations with other therapies. One of the adverse co...

    Authors: Zuxiang Yu, Chaoyu Xu, Bin Song, Shihao Zhang, Chong Chen, Changlong Li and Shuyu Zhang
    Citation: Journal of Translational Medicine 2023 21:708
  2. Bone marrow fibrosis represents an important structural change in the marrow that interferes with some of its normal functions. The aetiopathogenesis of fibrosis is not well established except in its primary f...

    Authors: Kanjaksha Ghosh, Durjoy K. Shome, Bipin Kulkarni, Malay K. Ghosh and Kinjalka Ghosh
    Citation: Journal of Translational Medicine 2023 21:703
  3. Nonalcoholic steatohepatitis (NASH) is a progressive and inflammatory subtype of nonalcoholic fatty liver disease (NAFLD) characterized by hepatocellular injury, inflammation, and fibrosis in various stages. M...

    Authors: Wei Shi, Guang Xu, Yuan Gao, Jun Zhao, Tingting Liu, Jia Zhao, Huijie Yang, Ziying Wei, Hui Li, An-Long Xu, Zhaofang Bai and Xiaohe Xiao
    Citation: Journal of Translational Medicine 2023 21:700
  4. Idiopathic pulmonary fibrosis (IPF) is fibrotic lung disease with no effective treatment. It is characterized by destruction of alveolar structure and pulmonary interstitial fibrosis, leading to dyspnea and ev...

    Authors: Jie Ji, Shudan Zheng, Yuxin Liu, Tian Xie, Xiaoyu Zhu, Yang Nie, Yi Shen and Xiaodong Han
    Citation: Journal of Translational Medicine 2023 21:640
  5. Progressive peritoneal fibrosis is a worldwide public health concern impacting patients undergoing peritoneal dialysis (PD), yet there is no effective treatment. Our previous study revealed that a novel compou...

    Authors: Shuting Li, Congwei Luo, Sijia Chen, Yiyi Zhuang, Yue Ji, Yiqun Zeng, Yao Zeng, Xiaoyang He, Jing Xiao, Huizhen Wang, Xiaowen Chen, Haibo Long and Fenfen Peng
    Citation: Journal of Translational Medicine 2023 21:639
  6. Peritoneal dialysis (PD) remains limited due to dialysis failure caused by peritoneal fibrosis. Tamoxifen (TAM), an inhibitor of estrogen receptor 1 (ESR1), has been reported to treat fibrosis, but the underly...

    Authors: Tingting Zhao, Zhengyu Sun, Xueli Lai, Hongtao Lu, Lulu Liu, Shuangxi Li, Ji-hang Yuan and Zhiyong Guo
    Citation: Journal of Translational Medicine 2023 21:614
  7. Non-alcoholic Fatty Liver Disease (NAFLD), now better known as Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD) and its progression to Nonalcoholic Steatohepatitis (NASH), more recently referred ...

    Authors: Paolo Convertini, Anna Santarsiero, Simona Todisco, Michele Gilio, Donatella Palazzo, Ilaria Pappalardo, Dominga Iacobazzi, Maria Frontuto and Vittoria Infantino
    Citation: Journal of Translational Medicine 2023 21:568
  8. Intestinal fibrosis is a common and severe complication of inflammatory bowel disease without clear pathogenesis. Abnormal expression of host genes and metabolic perturbations might associate with the onset of...

    Authors: Jinzhen Wu, Zhenyi Tian, Xiaoduan Zhuang, Yiru Chen, Tingting Fan, Jiayun Li and Xinying Wang
    Citation: Journal of Translational Medicine 2023 21:554
  9. Tumour necrosis factor superfamily protein 14 (TNFSF14), also called LIGHT, is an important regulator of immunological and fibrosis diseases. However, its specific involvement in cardiac fibrosis and atrial fi...

    Authors: Yirong Wu, Siyao Zhan, Lian Chen, Mingrui Sun, Miaofu Li, Xuanting Mou, Zhen Zhang, Linhao Xu and Yizhou Xu
    Citation: Journal of Translational Medicine 2023 21:544
  10. Renal interstitial fibrosis is a common pathway for the progressive development of chronic renal diseases (CKD) with different etiology, and is the main pathological basis leading to end-stage renal disease. A...

    Authors: Wei Xiong, Zhiyong Xiong, Anni Song, Chuntao Lei, Chen Ye, Hua Su and Chun Zhang
    Citation: Journal of Translational Medicine 2023 21:521
  11. Each step in angiogenesis is regulated by the extracellular matrix (ECM). Accumulating evidence indicates that ageing-related changes in the ECM driven by cellular senescence lead to a reduction in neovascular...

    Authors: Ping Xiao, Yanli Zhang, Yuting Zeng, Dehong Yang, Jiayao Mo, Ziting Zheng, Jilei Wang, Yuxin Zhang, Zhiyan Zhou, Xincen Zhong and Wenjuan Yan
    Citation: Journal of Translational Medicine 2023 21:457
  12. There are emerging studies suggesting that non-alcoholic fatty liver disease (NAFLD) is a heterogeneous disease with multiple etiologies and molecular phenotypes. Fibrosis is the key process in NAFLD progressi...

    Authors: Weiwei He, Yinxiang Huang, Xiulin Shi, Qingxuan Wang, Menghua Wu, Han Li, Qiuhong Liu, Xiaofang Zhang, Caoxin Huang and Xuejun Li
    Citation: Journal of Translational Medicine 2023 21:448
  13. Silica-induced pulmonary fibrosis (silicosis) is a diffuse interstitial fibrotic disease characterized by the massive deposition of extracellular matrix in lung tissue. Fibroblast to myofibroblast differentiat...

    Authors: Yaqian Qu, Ruonan Zhai, Dandan Wang, Zheng Wang, Guangjie Hou, Chenchen Wu, Meian Tang, Xiongbin Xiao, Jie Jiao, Yue Ba, Fang Zhou, Jian Qiu and Wu Yao
    Citation: Journal of Translational Medicine 2023 21:365
  14. Renal tubulointerstitial fibrosis is the hallmark of various chronic kidney diseases. Symmetric dimethylarginine (SDMA) is an independent cardiovascular risk factor in patients with chronic kidney diseases, wh...

    Authors: Yanzhe Wang, Ming Wu, Dongping Chen, Bo Tan, Pinglan Lin, Di Huang and Chaoyang Ye
    Citation: Journal of Translational Medicine 2023 21:326
  15. Pericyte-myofibroblast transition (PMT) has been confirmed to contribute to renal fibrosis in several kidney diseases, and transforming growth factor-β1 (TGF-β1) is a well-known cytokine that drives PMT. Howev...

    Authors: Liangmei Chen, Xiaofan Li, Yiyao Deng, Jianwen Chen, Mengjie Huang, Fengge Zhu, Zhumei Gao, Lingling Wu, Quan Hong, Zhe Feng, Guangyan Cai, Xuefeng Sun, Xueyuan Bai and Xiangmei Chen
    Citation: Journal of Translational Medicine 2023 21:323
  16. Hypertrophic scar is a fibrotic disease following wound healing and is characterized by excessive extracellular matrix deposition. Autologous microfat grafting proves an effective strategy for the treatment th...

    Authors: Qian Yu, Qiang Dai, Zonglin Huang, Chen Li, Li Yan, Xin Fu, Qian Wang, Yi Zhang, Lei Cai, Zhigang Yang and Ran Xiao
    Citation: Journal of Translational Medicine 2023 21:231
  17. Fibrosis, a process caused by excessive deposition of extracellular matrix (ECM), is a common cause and outcome of organ failure and even death. Researchers have made many efforts to understand the mechanism o...

    Authors: Yangdan Liu, Dongsheng Wen, Chiakang Ho, Li Yu, Danning Zheng, Steven O’Reilly, Ya Gao, Qingfeng Li and Yifan Zhang
    Citation: Journal of Translational Medicine 2023 21:164
  18. Authors: Monica Pernia Marin and Mary Salvatore
    Citation: Journal of Translational Medicine 2023 21:59